Tasigna Dosage

Generic name: nilotinib
Drug class: BCR-ABL tyrosine kinase inhibitors

Medically reviewed by  A Ras MD.

 

 Recommended Adult Dosing

Dosage forms:  CAP: 50 mg, 150 mg, 200 mg

Special Note

[uses, dosing may vary]
Info: refer to institution protocols and pkg insert prior to prescribing for uses and dosing incl. toxicity-related dose adjustments

Ph-positive CML

[chronic phase, newly diagnosed dz]
Dose: 300 mg PO q12h; Info: give on empty stomach, 1h before or 2h after food; may consider D/C tx if on nilotinib >3y w/ sustained molecular response; cont. monitoring BCR-ABL, CBC w/ diff after D/C q4wk x1y, then q6wk x1y, then q12wk thereafter; restart tx if molecular response lost; see pkg insert for detailed D/C and restart criteria
[chronic phase, resistant or intolerant dz]
Dose: 400 mg PO q12h; Info: give on empty stomach, 1h before or 2h after food; may consider D/C tx if on nilotinib >3y w/ sustained molecular response; cont. monitoring BCR-ABL, CBC w/ diff after D/C q4wk x1y, then q6wk x1y, then q12wk thereafter; restart tx if molecular response lost; see pkg insert for detailed D/C and restart criteria
[accelerated phase, resistant or intolerant dz]
Dose: 400 mg PO q12h; Info: give on empty stomach, 1h before or 2h after food

Renal dosing

[not defined]
renal impairment: not defined
HD/PD: not defined

Hepatic dosing

[newly diagnosed Ph-positive CML]
Child-Pugh Class A, B, or C: start 200 mg q12h; Info: monitor ECG closely
[resistant or intolerant Ph-positive CML]
Child-Pugh Class A or B: start 300 mg q12h; Child-Pugh Class C: start 200 mg q12h; Info: monitor ECG closely

 

SRC: NLM .